20-Jan-2026
Hollings researchers reveal why some pancreatic tumors behave differently
Medical University of South CarolinaPeer-Reviewed Publication
A new study led by MUSC Hollings Cancer Center researchers Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., sheds light on why pancreatic tumors with the KRAS G12R mutation behave less aggressively than those with more common KRAS mutations. Unlike typical KRAS-driven tumors, those fueled by G12R fail to activate key growth pathways in the same way and send weaker signals to the cell nucleus, slowing tumor growth. These tumors also create a gentler microenvironment, with less collagen and reduced cell movement, making them more responsive to treatment and less likely to spread. The findings reveal biological reasons why pancreatic cancer patients with G12R often have better outcomes and point to opportunities for more personalized treatment approaches.
- Journal
- Cancer Research
- Funder
- NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Institute of General Medical Sciences, U.S. Department of Defense, Pancreatic Cancer Action Network, Pancreatic Cancer Action Network, Concern Foundation, Mark Foundation For Cancer Research